Cardiovascular risk factor screening in systemic lupus erythematosus

Journal of Rheumatology

Volumn 30, Issue 3, 2003, Pages 493-496

  Al Herz, Adeeba ^a,b   Ensworth, Stephanie ^a   Shojania, Kamran ^a   Esdaile, John M ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b KUWAIT UNIVERSITY   (Kuwait)

^c ARTHRITIS RESEARCH CENTRE OF CANADA   (Canada)

Author keywords

Cardiovascular disease; Lupus; Risk factors; Screening

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID ANTIBODY; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FAMILY HISTORY; FEMALE; HIGH RISK POPULATION; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTENSION; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NEPHROTIC SYNDROME; OBESITY; POSTMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR; SCREENING; SMOKING; SYSTEMIC LUPUS ERYTHEMATOSUS; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; DIABETES MELLITUS; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; LIPIDS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MASS SCREENING; MEDICAL RECORDS; MIDDLE AGED; NEPHROTIC SYNDROME; RISK FACTORS; SMOKING;

EID: 0037333370     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Jacobsen S, Petersen J, Ullman S, et al. Mortality and causes of death of 513 Danish patients with systemic lupus erythematosus. Scand J Rheumatol 1999;28:75-80.
2. Manzi S, Selzer F, Sutton-Tyrrell K, et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999;42:51-60.
3. Lorenzo C, Rincon ID, Williams K, et al. High incidence of cardiovascular events in women with SLE compared to population-based controls [abstract]. Arthritis Rheum 2000;43 Suppl:S247.
4. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001;44:2331-7.
5. Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999;42:338-46.
6. Rahman P, Gladman DD, Urowitz MB, Hallett D, Tam LS. Early damage as measured by the SLICC/ACR damage index, a predictor of mortality in systemic lupus erythematosus. Lupus 2001;10:93-6.
7. Petri M, Perez-Gutthann S, Spence D, et al. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992;93:513-9.
8. Gladman DD, Urowitz MB. Morbidity in systemic lupus erythematosus. J Rheumatol 1987;14 Suppl 13:223-6.
9. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study. Am J Epidemiol 1997;145:408-15.
10. Hosenpud JD, Montanaro A, Hart MV, et al. Myocardial perfusion abnormalities on asymptomatic patients with systemic lupus erythematosus. Am J Med 1984;77:286-92.
11. Bruce IN, Burns RJ, Gladman DD, Urowitz MB. Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus. I. Prevalence and distribution of abnormalities. J Rheumatol 2000;27:2372-7.
12. Haider YS, Roberts WC. Coronary arterial disease in systemic lupus erythematosus; quantification of degrees of narrowing in 22 necropsy patients (21 women) aged 16 to 37 years. Am J Med 1981;70:775-81.
13. Fukumoto S, Tsumagari T, Kinjo M, Tanaka K. Coronary atherosclerosis in patients with systemic lupus erythematosus at autopsy. Acta Pathol Jpn 1987;37:1-9.
14. Urowitz MB, Bookman AAM, Koehler BE, et al. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976;60:221-5.
15. Ward MM, Pyun E, Studenski C. Causes of death in systemic lupus erythematosus: long-term follow up of an inception cohort. Arthritis Rheum 1995;38:1492-9.
16. Font, J, Ramos-Casals M, Cervera R, et al. Cardiovascular risk factors and the long-term outcome of lupus nephritis. QJM 2001;94:19-26.
17. Petri M. Predictors of atherosclerotic plaque on carotid duplex in SLE [abstract]. Arthritis Rheum 2000;43 Suppl:S247.
18. Rahman P, Aguero S, Gladman DD, et al. Vascular events in hypertensive patients with systemic lupus erythematosus. Lupus 2000;9:672-5.
19. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
20. Bruce IN, Gladman DD, Urowitz MB. Detection and modification of risk factors for coronary artery disease in patients with systemic lupus erythematosus: a quality improvement study. Clin Exp Rheumatol 1998;16:435-40.
21. Petri M, Spence D, Bone LR, Hochberg MC. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: Prevalence, recognition by patients, and preventive practices. Medicine 1992;71:291-302.
22. Bruce IN, Urowitz MB, Gladman DD, Hallett DC. Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol 1999;26:2137-43.
23. Shepherd J, Cobbe SM, Ford I, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Eng J Med 1995;333:1301-7.
24. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study. Lancet 1994;344:1383-9.
25. Hansson L, Zanchetti A, Carnuthers SG, et al. Effects of intensive blood-pressure lowering and low dose aspirin in the patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998;351:1755-62.
26. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng J Med 1993;329:927-34.
27. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type II diabetes (UKPDS 33). Lancet 1998;352:837-53.
28. Terres J, Becker P, Rosenberg A. Expected gain in life expectancy from various coronary heart disease risk factor modifications. Circulation 1999;83:1194-9.
29. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.
30. Mosca L, Collins P, Herrington DM, et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 2001;104:499-503.
31. Rahman P, Urowitz MB, Gladman DD, Bruce IN, Genest J. Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus. J Rheumatol 1999;26:2363-8.